Roundhill ETF Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| Novo Nordisk A/SNVO | 12.96% | $7.01M | 146,234 |
| Eli Lilly & CoLLY | 12.69% | $6.86M | 5,722 |
| Mount Vernon Liquid Assets Portfolio, LLCCash or money market | 9.93% | $5.37M | 5,371,409 |
| Pfizer IncPFE | 6.38% | $3.45M | 143,389 |
| Kailera Therapeutics IncKLRA | 6.21% | $3.36M | 152,501 |
| Viking Therapeutics IncVKTX | 5.86% | $3.17M | 81,186 |
| Amgen IncAMGN | 3.85% | $2.08M | 5,750 |
| AstraZeneca PLC | 3.83% | $2.07M | 10,931 |
| Roche Holding AG | 3.03% | $2.03M | 3,972 |
| Structure Therapeutics IncGPCR | 3.05% | $1.65M | 30,773 |
| MBX Biosciences IncMBX | 2.80% | $1.51M | 27,421 |
| Gilead Sciences IncGILD | 1.73% | $938.07K | 7,425 |
| Rhythm Pharmaceuticals IncRYTM | 1.64% | $884.46K | 7,966 |
| WaVe Life Sciences Ltd | 0.86% | $467.31K | 80,432 |
| CSPC Pharmaceutical Group Ltd | 5.32% | $366.76K | 3,236,000 |
| First American Government ObliCash or money market | 0.62% | $335.01K | 335,006 |
| Zealand Pharma A/S | 3.92% | $324.34K | 47,873 |
| Ascletis Pharma Inc | 4.20% | $289.51K | 1,686,000 |
| UNITED LAB | 2.63% | $181.22K | 1,322,000 |
| Jiangsu Hengrui Pharmaceutical | 2.58% | $177.98K | 189,200 |
| Hansoh Pharmaceutical Group Co | 2.54% | $175.32K | 364,000 |
| Innovent Biologics Inc | 2.36% | $163.09K | 126,000 |
| Gubra A/S | 1.87% | $155.06K | 20,597 |
| Chugai Pharmaceutical Co Ltd | 4.51% | $15.00K | 52,600 |
| Shionogi & Co Ltd | 1.24% | $4.13K | 39,100 |
| Hanmi Pharm Co Ltd | 3.50% | $1.22K | 7,386 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.